# A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

> **NCT04006145** · PHASE2 · COMPLETED · sponsor: **Albireo** · enrollment: 47 (actual)

## Conditions studied

- NAFLD
- NASH

## Interventions

- **DRUG:** Elobixibat
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04006145
- **Lead sponsor:** Albireo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-06
- **Primary completion:** 2020-06-26
- **Final completion:** 2020-07-15
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04006145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04006145, "A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04006145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*